216 related articles for article (PubMed ID: 37218360)
1. Inhibiting N-glycan processing increases the antibody binding affinity and effector function of human natural killer cells.
Rodriguez Benavente MC; Hughes HB; Kremer PG; Subedi GP; Barb AW
Immunology; 2023 Oct; 170(2):202-213. PubMed ID: 37218360
[TBL] [Abstract][Full Text] [Related]
2. Distinct CD16a features on human NK cells observed by flow cytometry correlate with increased ADCC.
Benavente MCR; Hakeem ZA; Davis AR; Murray NB; Azadi P; Mace EM; Barb AW
Sci Rep; 2024 Apr; 14(1):7938. PubMed ID: 38575779
[TBL] [Abstract][Full Text] [Related]
3. Restricted processing of CD16a/Fc γ receptor IIIa
Patel KR; Roberts JT; Subedi GP; Barb AW
J Biol Chem; 2018 Mar; 293(10):3477-3489. PubMed ID: 29330305
[TBL] [Abstract][Full Text] [Related]
4. Fc γ receptor IIIa/CD16a processing correlates with the expression of glycan-related genes in human natural killer cells.
Patel KR; Rodriguez Benavente MC; Lorenz WW; Mace EM; Barb AW
J Biol Chem; 2021; 296():100183. PubMed ID: 33310702
[TBL] [Abstract][Full Text] [Related]
5. Site-specific N-glycan Analysis of Antibody-binding Fc γ Receptors from Primary Human Monocytes.
Roberts JT; Patel KR; Barb AW
Mol Cell Proteomics; 2020 Feb; 19(2):362-374. PubMed ID: 31888963
[TBL] [Abstract][Full Text] [Related]
6. Characterization of in vitro antibody-dependent cell-mediated cytotoxicity activity of therapeutic antibodies - impact of effector cells.
Chung S; Lin YL; Reed C; Ng C; Cheng ZJ; Malavasi F; Yang J; Quarmby V; Song A
J Immunol Methods; 2014 May; 407():63-75. PubMed ID: 24704820
[TBL] [Abstract][Full Text] [Related]
7. Engineering of CD34+ progenitor-derived natural killer cells with higher-affinity CD16a for enhanced antibody-dependent cellular cytotoxicity.
van Hauten PMM; Hooijmaijers L; Vidal-Manrique M; van der Waart AB; Hobo W; Wu J; Blijlevens NMA; Jansen JH; Walcheck B; Schaap NPM; de Jonge PKJD; Dolstra H
Cytotherapy; 2024 Mar; 26(3):252-260. PubMed ID: 38127030
[TBL] [Abstract][Full Text] [Related]
8. Examination of IgG Fc Receptor CD16A and CD64 Expression by Canine Leukocytes and Their ADCC Activity in Engineered NK Cells.
Hullsiek R; Li Y; Snyder KM; Wang S; Di D; Borgatti A; Lee C; Moore PF; Zhu C; Fattori C; Modiano JF; Wu J; Walcheck B
Front Immunol; 2022; 13():841859. PubMed ID: 35281028
[TBL] [Abstract][Full Text] [Related]
9. Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells.
Snyder KM; Hullsiek R; Mishra HK; Mendez DC; Li Y; Rogich A; Kaufman DS; Wu J; Walcheck B
Front Immunol; 2018; 9():2873. PubMed ID: 30574146
[TBL] [Abstract][Full Text] [Related]
10. From CD16a Biology to Antibody-Dependent Cell-Mediated Cytotoxicity Improvement.
Coënon L; Villalba M
Front Immunol; 2022; 13():913215. PubMed ID: 35720368
[TBL] [Abstract][Full Text] [Related]
11. Allotype-specific processing of the CD16a N45-glycan from primary human natural killer cells and monocytes.
Patel KR; Roberts JT; Barb AW
Glycobiology; 2020 Jul; 30(7):427-432. PubMed ID: 31967297
[TBL] [Abstract][Full Text] [Related]
12. Primary Human Natural Killer Cells Retain Proinflammatory IgG1 at the Cell Surface and Express CD16a Glycoforms with Donor-dependent Variability.
Patel KR; Nott JD; Barb AW
Mol Cell Proteomics; 2019 Nov; 18(11):2178-2190. PubMed ID: 31467031
[TBL] [Abstract][Full Text] [Related]
13. An improved method to quantify human NK cell-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) per IgG FcR-positive NK cell without purification of NK cells.
Sung AP; Tang JJ; Guglielmo MJ; Redelman D; Smith-Gagen J; Bateman L; Hudig D
J Immunol Methods; 2018 Jan; 452():63-72. PubMed ID: 29113954
[TBL] [Abstract][Full Text] [Related]
14. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548
[TBL] [Abstract][Full Text] [Related]
15. Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy.
Nikkhoi SK; Li G; Eleya S; Yang G; Vandavasi VG; Hatefi A
Front Immunol; 2022; 13():1039969. PubMed ID: 36685519
[TBL] [Abstract][Full Text] [Related]
16. Detection of Antibody-Dependent Cell-Mediated Cytotoxicity-Supporting Antibodies by NK-92-CD16A Cell Externalization of CD107a: Recognition of Antibody Afucosylation and Assay Optimization.
Cruz Amaya J; Walcheck B; Smith-Gagen J; Lombardi VC; Hudig D
Antibodies (Basel); 2023 Jun; 12(3):. PubMed ID: 37489366
[TBL] [Abstract][Full Text] [Related]
17. Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity.
Zhu H; Blum RH; Bjordahl R; Gaidarova S; Rogers P; Lee TT; Abujarour R; Bonello GB; Wu J; Tsai PF; Miller JS; Walcheck B; Valamehr B; Kaufman DS
Blood; 2020 Feb; 135(6):399-410. PubMed ID: 31856277
[TBL] [Abstract][Full Text] [Related]
18. In Vivo Glycan Engineering via the Mannosidase I Inhibitor (Kifunensine) Improves Efficacy of Rituximab Manufactured in
Kommineni V; Markert M; Ren Z; Palle S; Carrillo B; Deng J; Tejeda A; Nandi S; McDonald KA; Marcel S; Holtz B
Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30621113
[TBL] [Abstract][Full Text] [Related]
19. The weaker-binding Fc γ receptor IIIa F158 allotype retains sensitivity to N-glycan composition and exhibits a destabilized antibody-binding interface.
Kremer PG; Barb AW
J Biol Chem; 2022 Sep; 298(9):102329. PubMed ID: 35921896
[TBL] [Abstract][Full Text] [Related]
20. iPSC-derived natural killer cells expressing the FcγR fusion CD64/16A can be armed with antibodies for multitumor antigen targeting.
Snyder KM; Dixon KJ; Davis Z; Hosking M; Hart G; Khaw M; Matson A; Bjordahl R; Hancock B; Shirinbak S; Miller JS; Valamehr B; Wu J; Walcheck B
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38056893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
